Last reviewed · How we verify
GCP-Service International West GmbH — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Intravenous 0.9% Sodium Chloride | Intravenous 0.9% Sodium Chloride | marketed | Crystalloid fluid / Electrolyte replacement solution | Fluid and electrolyte management |
Therapeutic area mix
- Fluid and electrolyte management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Dr. Waseem Ullah · 1 shared drug class
- Fayoum University Hospital · 1 shared drug class
- Hospital Central "Dr. Ignacio Morones Prieto" · 1 shared drug class
- Hospital Italiano de Buenos Aires · 1 shared drug class
- Hvidovre University Hospital · 1 shared drug class
- Hédi Chaker Hospital · 1 shared drug class
- Kecioren Education and Training Hospital · 1 shared drug class
- Krankenhaus Barmherzige Schwestern Linz · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for GCP-Service International West GmbH:
- GCP-Service International West GmbH pipeline updates — RSS
- GCP-Service International West GmbH pipeline updates — Atom
- GCP-Service International West GmbH pipeline updates — JSON
Cite this brief
Drug Landscape (2026). GCP-Service International West GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gcp-service-international-west-gmbh. Accessed 2026-05-17.